TY - JOUR T1 - Disinfection of SARS-CoV-2 using UVC reveals wavelength sensitivity contributes towards rapid virucidal activity JF - medRxiv DO - 10.1101/2021.06.30.21259769 SP - 2021.06.30.21259769 AU - Richard M. Mariita AU - Amy C. Wilson Miller AU - Rajul V. Randive Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/05/2021.06.30.21259769.abstract N2 - SARS-CoV-2 is a pathogen that can be disinfected using UVC. For effective inactivation strategies, design and implementation of UVC disinfection, knowledge of wavelength sensitivity, and disinfection rate of the relevant pathogen are required. This study aimed to determine the inactivation profile of SARS-CoV-2 using UVC irradiation with different wavelengths, in addition to validating surrogate models for SARS-CoV-2. Specifically, the study determined dosage, inactivation levels, and wavelength sensitivity of SARS-CoV-2. Assessment of SARS-CoV-2 (Strain USA/WA1-2020) inactivation at peak wavelength of 259, 268, 270, 275 and 280 nm was performed using plaque assay method. The UVC dose of 3.1 mJ/cm2 using 259 and 268 nm arrays yielded LRV2.32 and LRV2.44 respectively. With a dose of 5mJ/cm2, arrays of peak wavelengths at 259 and 268 nm obtained similar inactivation (LRV2.97 and LRV 2.80 respectively). The remaining arrays of longer wavelength, 270, 275 and 280 nm, demonstrated lower performances (LRV2.0 or less) with 5mJ/cm2. Additional study with the 268 nm array revealed that a dose of 6.25 mJ/cm2 (with 5 seconds or irradiation) is enough to obtain LRV3. These results determine that 259 and 268 nm are the most efficient wavelengths compared to longer UVC wavelengths, allowing the calculation of disinfection systems efficacy, and providing a benchmark for surrogates.Competing Interest StatementR.M. Mariita, A.C.W. Miller and R.V. Randive work for Crystal IS, an Asahi Kasei company that manufactures UVC LEDsFunding StatementThis research did not receive any specific grant from funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human or animal subjects were used in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal SARS-CoV-2 disinfection data and laboratory report is available upon reasonable request. Spectral confirmation data is available via https://doi.org/10.6084/m9.figshare.14884743.v1 https://doi.org/10.6084/m9.figshare.14884743.v1 ER -